First patient screened for MELD-ATG
26. November 2020
The first patient in the MELD-ATG trial has been screened in UZ Leuven. The idea of this INNODIA trial is to see whether ATG will stop the immune system from attacking the insulin producing β cells in the pancreas. More news following soon.
